CDRL news

Latest 1 stories · newest Jun 3, 2026

CDRL

Cadrenal Therapeutics CFO Matthew Szot separated from company effective May 28, 2026

Matthew K. Szot, Chief Financial Officer of Cadrenal Therapeutics, separated from the company on May 28, 2026, with a severance package of $365,806 payable in installments through September 2026. The departure represents a leadership change at the biopharmaceutical company during a period of operati…

Leadership Jun 3, 2026 sentiment -0.30 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same CDRL feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/CDRL/newsSTART FREE